GAGE2B Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q13066 |
---|---|
Clone Names | 91216134 |
Gene ID | 2574;645037 |
---|---|
Other Names | G antigen 2B/2C, GAGE-2B, GAGE-2C, Cancer/testis antigen 42, CT42, G antigen 2C, GAGE2B, GAGE2 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP13173a was selected from the N-term region of GAGE2B. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | GAGE2B |
---|---|
Synonyms | GAGE2 |
Function | Antigen, recognized on melanoma by autologous cytolytic T- lymphocytes. |
Tissue Location | Expressed in a variety of tumor tissues but not in normal tissues, except testis. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene belongs to a family of genes that are expressedin a variety of tumors but not in normal tissues, except for thetestis. The sequences of the family members are highly related butdiffer by scattered nucleotide substitutions. The antigenic peptideYRPRPRRY, which is also encoded by several other family members, isrecognized by autologous cytolytic T lymphocytes. [provided byRefSeq].
References
Sun, F., et al. Mol. Cancer Ther. 8(12):3191-3202(2009)Gjerstorff, M.F., et al. Tissue Antigens 71(3):187-192(2008)Ross, M.T., et al. Nature 434(7031):325-337(2005)De Backer, O., et al. Cancer Res. 59(13):3157-3165(1999)Scarcella, D.L., et al. Clin. Cancer Res. 5(2):335-341(1999)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.